Clinical Trials Browser

Phase 1/2 × Erlotinib Hydrochloride × 90 days × Clear all

NCT06483555 2026-04-23

PANGEA

Phase 1/2 Recruiting

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell